Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)